Market closedNon-fractional

Nuvalent/NUVL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Ticker

NUVL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

106

Nuvalent Metrics

BasicAdvanced
$5.1B
Market cap
-
P/E ratio
-$2.42
EPS
1.35
Beta
-
Dividend rate
$5.1B
1.35
20.926
20.697
-18.37%
-26.01%
7.49
7.49
-42.584
40.10%
-34.77%

What the Analysts think about Nuvalent

Analyst Ratings

Majority rating from 10 analysts.
Buy

Nuvalent Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$44M
16.23%
Profit margin
0.00%
NaN%

Nuvalent Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.44%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.51
-$0.59
-$0.62
-$0.69
-
Expected
-$0.53
-$0.58
-$0.60
-$0.68
-$0.76
Surprise
-3.15%
1.29%
3.18%
1.44%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nuvalent stock?

Nuvalent (NUVL) has a market cap of $5.1B as of July 23, 2024.

What is the P/E ratio for Nuvalent stock?

The price to earnings (P/E) ratio for Nuvalent (NUVL) stock is 0 as of July 23, 2024.

Does Nuvalent stock pay dividends?

No, Nuvalent (NUVL) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Nuvalent dividend payment date?

Nuvalent (NUVL) stock does not pay dividends to its shareholders.

What is the beta indicator for Nuvalent?

Nuvalent (NUVL) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Nuvalent stock

Buy or sell Nuvalent stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing